High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT): A Prospective Real-World Cohort Study in the Qinghai-Tibet Plateau

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau. Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, together with their donors, are systematically enrolled. The registry collects demographic, diagnostic, treatment, prognosis, and medical expense information, as well as biospecimens for future analyses. Historical data are incorporated, and prospective data collection is ongoing with long-term follow-up planned. The registry is designed as a sustainable research infrastructure to provide comprehensive data on disease incidence, treatment patterns, outcomes, and resource utilization in a high-altitude setting.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023.

• Planned or actual hematopoietic stem cell transplantation (HSCT).

• Provision of signed informed consent.

Locations
Other Locations
China
Affiliated Hospital of Qinghai University
RECRUITING
Xining
Contact Information
Primary
Yigeng CAO, MD,PhD
caoyigeng@ihcams.ac.cn
+8618622477066
Backup
Hui Geng
gh0227@sina.com
+8618729989935
Time Frame
Start Date: 2023-09-01
Estimated Completion Date: 2100-12-31
Participants
Target number of participants: 1000
Treatments
HSCT Patients and Donors
Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, and their related or unrelated stem cell donors. Participants are prospectively followed for clinical outcomes and biospecimen collection under real-world conditions.
Sponsors
Leads: Yigeng Cao,MD,PhD

This content was sourced from clinicaltrials.gov

Similar Clinical Trials